{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:12:41Z","timestamp":1793610761255,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS094218"],"award-info":[{"award-number":["R01NS094218"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS094218"],"award-info":[{"award-number":["R01NS094218"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Surg Int"],"DOI":"10.1007\/s00383-023-05523-w","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:02:06Z","timestamp":1690484526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Concurrent application of interferon-gamma and vincristine inhibits tumor growth in an orthotopic neuroblastoma mouse model"],"prefix":"10.1007","volume":"39","author":[{"given":"Jasmine","family":"Zeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcin","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"5523_CR1","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","volume":"2","author":"KK Matthay","year":"2016","unstructured":"Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L et al (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"5523_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/jnci\/djp230","volume":"101","author":"C Laverdiere","year":"2009","unstructured":"Laverdiere C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M et al (2009) Long-term outcomes in survivors of neuroblastoma: a report from the childhood cancer survivor study. J Natl Cancer Inst 101(16):1131\u20131140","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"5523_CR3","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324\u20131334","journal-title":"N Engl J Med"},{"issue":"5","key":"5523_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ijc.2910550521","volume":"55","author":"M Ponzoni","year":"1993","unstructured":"Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P (1993) Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer 55(5):817\u2013823","journal-title":"Int J Cancer"},{"issue":"7","key":"5523_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1084\/jem.20020666","volume":"196","author":"Y Refaeli","year":"2002","unstructured":"Refaeli Y, Van Parijs L, Alexander SI, Abbas AK (2002) Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 196(7):999\u20131005","journal-title":"J Exp Med"},{"issue":"11","key":"5523_CR6","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/sj.bjc.6601842","volume":"90","author":"I Airoldi","year":"2004","unstructured":"Airoldi I, Meazza R, Croce M, Di Carlo E, Piazza T, Cocco C et al (2004) Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity. Br J Cancer 90(11):2210\u20132218","journal-title":"Br J Cancer"},{"issue":"10","key":"5523_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11(10):889\u2013896","journal-title":"Nat Immunol"},{"issue":"7","key":"5523_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399\u2013416","journal-title":"Nat Rev Clin Oncol"},{"key":"5523_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","volume":"6","author":"FO Martinez","year":"2014","unstructured":"Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6:13","journal-title":"F1000Prime Rep."},{"issue":"6","key":"5523_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","volume":"82","author":"GH Windbichler","year":"2000","unstructured":"Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J et al (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82(6):1138\u20131144","journal-title":"Br J Cancer"},{"issue":"9","key":"5523_CR11","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1021\/acs.molpharmaceut.8b00564","volume":"15","author":"Y Yin","year":"2018","unstructured":"Yin Y, Hu Q, Xu C, Qiao Q, Qin X, Song Q et al (2018) Co-delivery of doxorubicin and interferon-\u03b3 by thermosensitive nanoparticles for cancer immunochemotherapy. Mol Pharm 15(9):4161\u20134172","journal-title":"Mol Pharm"},{"issue":"6","key":"5523_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.surg.2020.01.012","volume":"167","author":"JS Taylor","year":"2020","unstructured":"Taylor JS, Yavuz B, Zeki J, Wood L, Ikegaki N, Coburn J et al (2020) Enhancing sustained-release local therapy: single versus dual chemotherapy for the treatment of neuroblastoma. Surgery 167(6):969\u2013977","journal-title":"Surgery"},{"issue":"10","key":"5523_CR13","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/nprot.2011.379","volume":"6","author":"DN Rockwood","year":"2011","unstructured":"Rockwood DN, Preda RC, Yucel T, Wang X, Lovett ML, Kaplan DL (2011) Materials fabrication from bombyx mori silk fibroin. Nat Protoc 6(10):1612\u20131631","journal-title":"Nat Protoc"},{"issue":"11","key":"5523_CR14","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1093\/emboj\/16.11.2985","volume":"16","author":"WA Weiss","year":"1997","unstructured":"Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985\u20132995","journal-title":"EMBO J"},{"issue":"3","key":"5523_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ijc.30479","volume":"140","author":"J Coburn","year":"2017","unstructured":"Coburn J, Harris J, Zakharov AD, Poirier J, Ikegaki N, Kajdacsy-Balla A et al (2017) Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment. Int J Cancer 140(3):726\u2013735","journal-title":"Int J Cancer"},{"key":"5523_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41\u2013101","journal-title":"Adv Immunol"},{"issue":"19","key":"5523_CR17","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G (2011) The two faces of interferon-\u03b3 in cancer. Clin Cancer Res 17(19):6118\u20136124","journal-title":"Clin Cancer Res"},{"key":"5523_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","volume":"1182","author":"CH Miller","year":"2009","unstructured":"Miller CH, Maher SG, Young HA (2009) Clinical Use of interferon-gamma. Ann N Y Acad Sci 1182:69\u201379","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"5523_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ygyno.2009.02.007","volume":"113","author":"KM Schmeler","year":"2009","unstructured":"Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL et al (2009) A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 113(2):210\u2013215","journal-title":"Gynecol Oncol"},{"issue":"4","key":"5523_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707\u2013723","journal-title":"Cell"},{"issue":"15","key":"5523_CR21","first-page":"4490","volume":"63","author":"AK Nowak","year":"2003","unstructured":"Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63(15):4490\u20134496","journal-title":"Cancer Res"},{"issue":"3","key":"5523_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119751","volume":"10","author":"E Derlindati","year":"2015","unstructured":"Derlindati E, Dei Cas A, Montanini B, Spigoni V, Curella V, Aldigeri R et al (2015) Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation? PLoS ONE 10(3):e0119751","journal-title":"PLoS ONE"},{"issue":"3","key":"5523_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12094-015-1373-0","volume":"18","author":"W Hu","year":"2016","unstructured":"Hu W, Li X, Zhang C, Yang Y, Jiang J, Wu C (2016) Tumor-associated macrophages in cancers. Clin Transl Oncol 18(3):251\u2013258","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"5523_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/stem.2801","volume":"36","author":"T Relation","year":"2018","unstructured":"Relation T, Yi T, Guess AJ, La Perle K, Otsuru S, Hasgur S et al (2018) Intratumoral delivery of interferon\u03b3-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation In Vivo. Stem Cells 36(6):915\u2013924","journal-title":"Stem Cells"},{"issue":"12","key":"5523_CR25","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.18632\/oncotarget.1376","volume":"4","author":"E Mira","year":"2013","unstructured":"Mira E, Carmona-Rodriguez L, Tardaguila M, Azcoitia I, Gonzalez-Martin A, Almonacid L et al (2013) A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget 4(12):2288\u20132301","journal-title":"Oncotarget"},{"issue":"3","key":"5523_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7785\/tcrt.2012.500312","volume":"12","author":"C Lan","year":"2013","unstructured":"Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T et al (2013) Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 12(3):259\u2013267","journal-title":"Technol Cancer Res Treat"},{"issue":"36","key":"5523_CR27","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1200\/JCO.2005.05.3314","volume":"24","author":"CM Coughlin","year":"2006","unstructured":"Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X et al (2006) Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 24(36):5725\u20135734","journal-title":"J Clin Oncol"},{"issue":"1","key":"5523_CR28","doi-asserted-by":"publisher","first-page":"16695","DOI":"10.1038\/s41598-020-73695-9","volume":"10","author":"ER Webb","year":"2020","unstructured":"Webb ER, Lanati S, Wareham C, Easton A, Dunn SN, Inzhelevskaya T et al (2020) Immune characterization of pre-clinical murine models of neuroblastoma. Sci Rep 10(1):16695","journal-title":"Sci Rep"},{"issue":"3","key":"5523_CR29","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23618","volume":"2","author":"LM Carlson","year":"2013","unstructured":"Carlson LM, De Geer A, Sveinbjornsson B, Orrego A, Martinsson T, Kogner P et al (2013) The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology 2(3):e23618","journal-title":"Oncoimmunology"},{"issue":"3","key":"5523_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1158\/0008-5472.CAN-18-2139","volume":"79","author":"L Fultang","year":"2019","unstructured":"Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F et al (2019) Macrophage-derived IL1\u03b2 and TNF\u03b1 regulate arginine metabolism in neuroblastoma. Cancer Res 79(3):611\u2013624","journal-title":"Cancer Res"},{"issue":"1","key":"5523_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s40425-019-0823-6","volume":"7","author":"J Voeller","year":"2019","unstructured":"Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A et al (2019) Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. J Immunother Cancer 7(1):344","journal-title":"J Immunother Cancer"},{"issue":"5","key":"5523_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-015-1663-y","volume":"64","author":"M Kroesen","year":"2015","unstructured":"Kroesen M, Brok IC, Reijnen D, van Hout-Kuijer MA, Zeelenberg IS, Den Brok MH et al (2015) Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents. Cancer Immunol Immunother 64(5):563\u2013572","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"5523_CR33","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/ijc.28463","volume":"134","author":"M Kroesen","year":"2014","unstructured":"Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L et al (2014) A transplantable TH-MYCN transgenic tumor model in C57Bl\/6 mice for preclinical immunological studies in neuroblastoma. Int J Cancer 134(6):1335\u20131345","journal-title":"Int J Cancer"}],"container-title":["Pediatric Surgery International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00383-023-05523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00383-023-05523-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00383-023-05523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:29:18Z","timestamp":1702578558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00383-023-05523-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5523"],"URL":"https:\/\/doi.org\/10.1007\/s00383-023-05523-w","relation":{},"ISSN":["1437-9813"],"issn-type":[{"value":"1437-9813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"12 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"241"}}